| Identification | Back Directory | [Name]
2'',3'',5''-Triacetyl -azacytidine | [CAS]
10302-78-0 | [Synonyms]
Nsc291930
2',3',5'-triacetyl-5-Azacytidine
2'',3'',5''-Triacetyl -azacytidine
S-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-, triacetate (ester)
1,3,5-Triazin-2(1H)-one, 4-aMino-1-(2,3,5-tri-O-acetyl-b-D-ribofuranosyl)-
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2,3,5-tri-o-acetyl-.beta.-D-ribofuranosyl)-
(2R,3R,4R,5R)-2-(Acetoxymethyl)-5-(4-amino-2-oxo-1,3,5-triazin-1(2H)-yl)tetrahydrofuran-3,4-diyl diacetate | [Molecular Formula]
C14H18N4O8 | [MDL Number]
MFCD11113159 | [MOL File]
10302-78-0.mol | [Molecular Weight]
370.316 |
| Chemical Properties | Back Directory | [Appearance]
White to off-white powder | [Boiling point ]
497.3±55.0 °C(Predicted) | [density ]
1.60±0.1 g/cm3(Predicted) | [storage temp. ]
Store at 0-5°C | [solubility ]
≤30mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | [form ]
crystalline solid | [pka]
3.06±0.20(Predicted) | [CAS DataBase Reference]
10302-78-0 |
| Hazard Information | Back Directory | [Chemical Properties]
White to off-white powder | [Uses]
5-Azacytidine is an inhibitor of DNA methyltransferaes, potentially serving to reverse epigenetic changes. It reduces hypermethylation associated with certain diseases, including myelodysplastic syndromes and cancer. 2’,3’,5’-triacetyl-5-Azacytidine is a prodrug form of 5-azacytidine that may be rapidly absorbed orally without formation of major metabolites in the gastrointestinal tract.[Cayman Chemical] | [Description]
5-Azacytidine is an inhibitor of DNA methyltransferase, potentially serving to reverse epigenetic changes.1 It reduces hypermethylation associated with certain diseases, including myelodysplastic syndromes and cancer.2,3,4 2’,3’,5’-triacetyl-5-Azacytidine is a prodrug form of 5-azacytidine that may be rapidly absorbed orally without formation of major metabolites in the gastrointestinal tract. | [in vivo]
in cd-1 mice, oral administration of tac for five days per week for 2 weeks didn’t result in animal deaths and weight loss, but induced changes in hematological parameters, lymph nodes, bone marrow, and duodenal epithelium. tac inhibited global dna methylation in the spleen and gut. in an in vivo l1210 leukemia model, tac exhibited antineoplastic activity [1]. | [storage]
Store at -20°C | [References]
[1] ziemba a, ramirez m c, freeman b, et al. abstract# 3369: development of oral demethylating agents for the treatment of myelodysplastic syndrome[j]. 2009.
[2] brueckner b, boy r g, siedlecki p, et al. epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human dna methyltransferases[j]. cancer research, 2005, 65(14): 6305-6311. |
|
|